The proverbial ‘pill’ or hormonal contraception may be available over-the-counter (or at least a progestin-only version) by year’s end. Join guest host, Jake Galdo, as he discusses improved access to care with Erin Raney as the FDA debates over-the-counter status for hormonal contraceptives.

The GameChanger
Women’s health is a priority area from a public health perspective – the US has lots of room for improvement. One initiative is to allow a progestin-only hormonal contraceptive have over-the-counter status; in other words, be available without prescription. Progestin-only therapy has unique counseling considerations, so pharmacy intervention can help to optimize care.

Show Segments
[insert here]

Host
Jake Galdo, PharmD, MBA, BCPS, BCGP
Course Content and Developer, CEimpact
Managing Network Facilitator, CPESN Health Equity
CEO, Seguridad

Guest
Erin C. Raney, Pharm.D., BCPS, BC-ADM
Professor of Pharmacy Practice
Midwestern University College of Pharmacy-Glendale

References and Resources

Opill Rx-to-OTC Switch Program. www.fda.gov/media/167893/download

Redeem your CPE here
CPE (Pharmacist) https://learn.ceimpact.com/library/course/5768

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)
Pharmacists: Get a membership https://www.ceimpact.com/

CE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the efficacy of OTC hormonal contraceptive
2. Identify contraindications for OTC hormonal contraceptives

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-XXX-H01-P
Initial release date: XX/XX/2023
Expiration date: XX/XX/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Download the CEimpact App for Free Continuing Education + so much more!